Disc Medicine, a privately-held, clinical-stage biopharmaceutical company, completed the merger with Gemini, a clinical-stage precision medicine company, in a $175m deal. “The completion of this merger and concurrent financing marks a transformative moment in Disc’s growth and ensures we are well-positioned to advance our portfolio of innovative, potentially first-in-class therapeutic candidates through key development milestones. We’re excited to enter the new year with multiple programs already in the clinic, a robust development pipeline and the financial strength from this merger. We look forward to maintaining this momentum and reporting on interim data read-outs from several patient studies in 2023,” John Quisel, Disc CEO and President.